Which weight loss injection is best for prediabetes?

Step 1: understand what the evidence actually shows for prediabetes

Prediabetes sits in a grey zone, blood glucose above the healthy range but short of a type 2 diabetes diagnosis. Clinicians have long known that losing 5–10% of body weight can bring blood glucose back toward normal in many people; losing significantly more makes that outcome more likely. That is where these injections become relevant.

Tirzepatide works on two gut-hormone pathways (GIP and GLP-1), slowing digestion, reducing appetite and improving how the body handles blood sugar. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants without diabetes lost around 20–21% of their body weight on average at the highest dose over 72 weeks. Semaglutide (Wegovy) acts on the GLP-1 pathway alone; its STEP 1 trial showed roughly 15% average weight reduction over 68 weeks. Both figures are for people without type 2 diabetes, a group that overlaps heavily with people who have prediabetes.

Neither medicine is licensed for prediabetes as a standalone indication. What they are licensed for is weight management, and your prescriber may consider that weight loss is the right clinical goal here. Exploring the relationship between these injections and blood sugar conditions helps clarify where the evidence sits.

Step 2: check whether you meet the eligibility criteria

UK licensing for both Mounjaro and Wegovy requires a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Prediabetes itself is not explicitly listed in the SmPCs as a qualifying condition in the same way as established type 2 diabetes, hypertension or obstructive sleep apnoea, so a prescriber will look carefully at your overall clinical picture.

In practice, many people with prediabetes also carry at least one other qualifying condition. High blood pressure, raised cholesterol and joint problems are common travel companions. If you have one of those alongside prediabetes and a BMI of 27 or above, you may well meet the private prescribing threshold. The NICE appraisal of tirzepatide (TA1026) sets out the NHS eligibility criteria in detail, which are stricter than private criteria and involve a phased rollout. On the NHS, eligibility for weight management medicines remains tightly gated for now.

BMI is a starting point, not a verdict. A good prescriber also considers your HbA1c trend, family history of type 2 diabetes, cardiovascular risk, and what other treatments you are already using. You can read more about how these injections sit within diabetes-related care to understand the full picture before you consult.

Step 3: know what the consultation will cover, and what to expect afterwards

A responsible consultation for someone with prediabetes will involve more than a quick eligibility tick-box. Your prescriber will want to understand your blood glucose history, current medications (metformin and some other medicines interact with GLP-1 therapies), and whether your prediabetes has been formally confirmed by a GP. If you have not had a recent HbA1c test, it is worth getting one before your consultation, it gives the prescriber a clearer baseline.

At nume, every application is personally read by a GPhC-registered independent prescriber, never passed to an automated filter. Our prescribers are familiar with the clinical questions that prediabetes raises; our clinical team is there if you want to understand more about how we approach complex situations. If approved, your treatment arrives via DPD the next working day in a plain, unbranded box, a discreet parcel that gives nothing away on the doorstep, with a tracking link on your phone so you know exactly when to be in.

You should also know what to watch for once treatment starts. Some people with prediabetes are considering extreme weight loss injections, and understanding how the most aggressive doses behave is important before committing to a treatment plan. Severe, persistent stomach pain that reaches through to your back needs prompt medical attention, the MHRA issued a Drug Safety Update on GLP-1 medicines and pancreatitis in January 2026 underlining this point. Any suspected side effects can be reported at Yellow Card.

What's still uncertain, and who to involve

The evidence that weight loss helps prediabetes is strong; the evidence that these injections specifically reverse prediabetes as a pharmacological effect (separate from the weight loss they produce) is more nuanced. Trials were not designed to use prediabetes remission as the primary endpoint. What the SURMOUNT and STEP programmes do show is that substantial, sustained weight loss changes metabolic markers, and for many people with prediabetes, that is clinically meaningful.

What is less certain: how long the benefit lasts if treatment stops, whether the same blood-sugar improvements occur at lower doses (most trial participants were titrated to the highest doses), and what the optimal path looks like if your prediabetes progresses despite treatment. These are questions worth discussing with your GP or diabetes care team alongside any private prescription service. Our prescribers can advise on treatment and flag when specialist input would add value.

If you are ready to take the next step, our free consultation is the place to start. You can also review the safety profile of diabetes-related injections for weight loss and check what this treatment typically costs before you decide.